Vitiligo is the most common cause of depigmentation worldwide, with immunosuppressive treatments often being inefficient and prone to recurrence, making it essential to identify new therapeutic targets. Periplakin (PPL) has been identified and confirmed as a key factor in vitiligo-related depigmentation. Based on this, a series of selective PPL agonists, specifically benzenesulfonamides, have been developed. Among these, compound exhibits superior efficacy compared to ruxolitinib, the only FDA-approved treatment for vitiligo. has been shown to increase cAMP levels by regulating PPL, which enhances MITF expression, a key transcription factor in melanin biosynthesis. Additionally, promotes melanin production by regulating tryptophan metabolism. In summary, PPL is a promising drug target, and has strong potential for future treatment of vitiligo due to its high selectivity and favorable druggability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.4c01717 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bacillus subtilis-derived-exopolysaccharide halts depigmentation and autoimmunity in vitiligo.
J Invest Dermatol
December 2024
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago (IL), USA; Department of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA. Electronic address:
Vitiligo has a complex multifactorial etiology involving a T-cell mediated autoimmune response to cutaneous melanocytes. Microbial dysbiosis has been assigned a contributing role in vitiligo etiology. Treating vitiligo can be a challenging task and finding novel treatment approaches is crucial.
View Article and Find Full Text PDFBiologic drugs induced vitiligo: case reports and review of literature.
Front Immunol
January 2025
Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Biological drugs are extensively used to treat various inflammatory diseases, including psoriasis, atopic dermatitis (AD), and rheumatoid arthritis. While generally effective and safe, these therapies have been increasingly associated with secondary development of vitiligo, especially with anti-TNF α and anti-IL17 drugs. Dupilumab, an IL-4 receptor alpha antagonist used in moderate to severe AD, rarely induces vitiligo.
View Article and Find Full Text PDFSegmental vitiligo: autoimmune pathogenesis, neuronal mechanisms, and somatic mosaicism.
Int J Dermatol
December 2024
Department of Dermatology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Vitiligo is a common depigmentation disorder classified into nonsegmental vitiligo (NSV) and segmental vitiligo (SV). SV accounts for 5-27.9% of patients with vitiligo.
View Article and Find Full Text PDFAn Overview of the Biological Complexity of Vitiligo.
Oxid Med Cell Longev
December 2024
Center for Global Health, Università Cattolica del Sacro Cuore (UCSC), Rome, Italy.
Vitiligo is a skin disease that affects all ethnicities and genders and is characterized by the loss of pigment essentially due to the selective loss of melanocytes. Although it is generally considered a systemic disease associated with polymorphisms in genes involved in the immune response, vitiligo is also considered an oxidative imbalance-associated disease. It represents a multifactorial pathology in which some genetic predisposition and epigenetic factors coupled with some critical biochemical and molecular pathways could play a pivotal role.
View Article and Find Full Text PDFStudy to evaluate effect of oral mini pulse corticosteroid therapy for unstable vitiligo on hypothalamic pituitary adrenal axis suppression.
Med J Armed Forces India
December 2024
Commanding Officer, 180 Military Hospital, C/o 99 APO, India.
Background: The treatment of vitiligo is difficult and usually requires prolonged therapy. All exogenous glucocorticoid therapies can lead to the hypothalamic-pituitary-adrenal axis (HPA) suppression. Steroid therapy in the form of an intermittent pulse therapy is a much safer option than daily administration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!